MiNK Therapeutics
@MiNK_iNKT
Followers
706
Following
557
Media
141
Statuses
441
MiNK is a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf, $INKT cell therapies to treat cancer and other immune-mediated diseases
New York, NY
Joined March 2018
New research just published: MiNK-215 helps break down the barriers that protect tough-to-treat solid tumors and wakes up the immune system to fight back. A promising step forward for patients with limited options. Read: https://t.co/dhDDS91ANO
#CancerResearch #Immunotherapy
aacrjournals.org
Abstract. Cellular immunotherapies show remarkable efficacy against hematological malignancies. However, applying these therapies against solid tumors is challenging. Among the obstacles are the lack...
0
1
2
MiNK reports Q3 2025 results: durable #agenT797 responses, NIH-funded GvHD trial launch & leadership expansion driving pivotal readiness across oncology, inflammation & transplantation. Read more 🔗 https://t.co/vVZQtOVm6K
#CellTherapy #Immunotherapy #iNKT
1
0
1
New #SITC25 data: MiNK’s allo-iNKT therapy #agenT797 delivers durable responses & immune reactivation in PD-1–refractory solid tumors, including remissions lasting 2+ yrs. Favorable safety + broad activity. Press release: https://t.co/vVZQtOUOhc Poster: https://t.co/W8YYEWGyUo
0
2
3
MiNK Therapeutics will report Q3 2025 financial results & share updates on Fri, Nov 14 @ 8:30 a.m. ET. Registration Link🔗: https://t.co/jdaQdQfl26 Read Release: https://t.co/A2cY5MIreJ
#MiNK #CellTherapy #Earnings #Biotech #agenT797
0
0
1
MiNK Therapeutics to present late-breaking #SITC25 data on AgenT-797 showing durable activity in solid tumors. https://t.co/ht5002WjGB 📍 Poster #1344 📅 Sat, Nov 8 🕐 12:15–1:45 & 5:10–6:35 p.m. ET 👨⚕️ Dr. Benjamin Garmezy, Sarah Cannon Research Institute #iNKT #CellTherapy
0
0
2
We’re excited to welcome COL (Ret.) John B. Holcomb, MD to our Board! A trauma & immune medicine legend—John brings decades of leadership in combat casualty care, critical care, & translational science. His guidance comes at a key moment as MiNK enters late-stage dev.
0
0
0
LIVE from #CARTCRSummit2025 🧬 MiNK CEO Dr. Jennifer Buell presents first-in-human data on iNKT cell therapy in immune collapse + strategy for broad off-the-shelf use in autoimmune & pulmonary disease. Cell therapy beyond oncology is here. #CellTherapy #iNKT #Autoimmune #MiNK
0
0
5
We’re thrilled to welcome Dr. Terese Hammond (@TereseH20145) as Head of Inflammatory & Pulmonary Diseases. A leader in pulmonary medicine, Dr. Hammond will advance our pivotal trials in ARDS, GVHD & more. Read the release: https://t.co/0HvXqhDPTD
0
1
2
Dr. @BGarmezy and colleagues share the science and the story behind a remarkable response in metastatic testicular cancer—using allogeneic iNKT cells. Watch: https://t.co/Rq0wX1Zc6i Read: https://t.co/Ytm77yO38t
#iNKTcells #CellTherapy #TesticularCancer #Immunotherapy
0
0
3
Join us for our Q2 2025 Earnings & Webcast today @ 8:30am EST as we review key updates and strategic progress. 🔗Listen live: https://t.co/HsT3oJ0qQv 🔗 Read the release here: https://t.co/lP1rMq6GAj
#inkt #Biotech #Earnings #Q22025
0
0
2
New peer-reviewed case study in Oncogene describes our allogeneic iNKT cell therapy, agenT-797, clinical response in metastatic, treatment-refractory testicular cancer. Promising immune activity seen in combo with anti–PD-1 therapy. Read here: https://t.co/kzMmZO0J7g
3
1
9
MiNK has been awarded a NIAID grant to advance its allo-iNKT cell therapy for patients undergoing stem cell transplant. This non-dilutive funding supports collaborative research with the University of Wisconsin. Learn more: https://t.co/8K54beatSU.
#CellTherapy #NIH #INKT
0
0
1
Yesterday at #AACRIO25, we presented new translational insights highlighting the powerful synergy between MiNK’s allo-iNKT cells, checkpoint inhibitors, and chemotherapy in #GastricCancer. Read more about the data: https://t.co/xZPYTY3xb4
0
0
2
MiNK is live in Los Angeles for #AACRIO25. Tune in later today to hear new translational data from the ongoing Ph2 study evaluating allo-iNKTs (agenT-797) in combination with @Agenus_Bio's BOT/BAL & chemotherapy in refractory #GastricCancer. Learn more: https://t.co/xZPYTY3xb4
0
1
3
We are excited to announce a new collaboration with Autonomous Therapeutics. By combining our iNKT cell platform with their encrypted RNA technology, we aim to develop innovative and potentially transformative therapies for metastatic cancers. Learn more: https://t.co/kJTt9M2rDn
0
0
1
Bot/Bal #immunotherapy in #coloncancer #NEST 1/2 @Agenus_Bio with very promising data in early MSI-s/MSI-H #coloncancer ! @myESMO #ESMOGI24 #ESMOAmbassadors @OncoAlert #CancerResearch #cancer
4
23
77
Yesterday Dr. Terese Hammond presented data at the American Thoracic Society #ATS2024 Annual Meeting in San Diego, CA, showcasing the clinical activity of MiNK’s allogeneic iNKT cells in respiratory distress. Learn more: https://t.co/hZLldjFcgf
0
1
5
This quarter we made significant strides across our iNKT cell programs, including generating clinical data from our agenT-797 program, strengthening our financial position, and advancing our innovative next-generation therapies. Read more in our Q1 report: https://t.co/bNqsIfEShY
0
0
3
Today we’ve announced a $5.8M in private placement financing to accelerate MiNK-215's clinical development and the appointment of a Board Observer. Learn more: https://t.co/72y22jbcqI
0
1
4
#ICYMI - check out our presentation from #AACR2024 yesterday: https://t.co/cdKLRneK9I Thank you to everyone who stopped by our poster session to hear new preclinical data on MiNK-215’s activity against colorectal cancer liver metastases. #CellTherapy #CancerResearch #INKT
1
1
2